Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL622751 | 1.00 | HDAC6 (0.54) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL622318 | 1.00 | HDAC6 (0.54) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL30262738 | 0.85 | HDAC3 (0.45) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL19871362 | 0.80 | CYP2D6 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL9953255 | 0.80 | CYP2D6 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL16842413 | 0.78 | HDAC3 (0.33) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL24445633 | 0.77 | HDAC3 (0.41) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL14524872 | 0.77 | HDAC3 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL28507298 | 0.77 | HDAC3 (0.44) | HDAC6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL16447084 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119306599-A | Preparation method of R-3-hydroxypent-4-enoate tert-butyl ester | 佛山奕安赛医药科技有限公司 | 2025-01-14 | — | — | CN | claimed |
| US-20250064838-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2025-02-27 | — | — | US | disclosed |
| CN-119306599-A | Preparation method of R-3-hydroxypent-4-enoate tert-butyl ester | 佛山奕安赛医药科技有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-12171772-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4356736-A2 | SYNTHESIS OF BORONATE SALTS | Melinta Therapeutics, Inc. (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-3604316-B1 | SYNTHESIS OF BORONATE SALTS | MELINTA THERAPEUTICS INC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2023-09-07 | — | — | US | disclosed |
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2023-09-07 | — | — | US | disclosed |
| US-11684629-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11684629-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2013122888-A2 | METHODS OF TREATING BACTERIAL INFECTIONS | REMPEX PHARMACEUTICALS, INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2603514-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| US-20120040932-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040932-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2012021455-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20110217335-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2011-09-08 | — | — | US | disclosed |
| US-20110217335-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2011-09-08 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | NEXGENIX PHARMACEUTICALS HOLDINGS, INC. | 2010-11-18 | — | — | US | disclosed |
| WO-2009091921-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | UNIVERSITE DE STRASBOURG (FR) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040932-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BCL9 | HDAC6 849/4885HDAC3 2302/4885HDAC1 2058/4885 |
| US-20100292218-A1 | Treatment Of Neurofibromatosis With Radicicol And Its Derivatives | HSP90AB2P, HSP90AA1, HSPA2 | HDAC6 1232/4885HDAC3 3466/4885HDAC1 3038/4885 |
| US-20110217335-A1 | SYNTHESIS OF RESORCYLIC ACID LACTONES USEFUL AS THERAPEUTIC AGENTS | HSP90AA1, HSP90AB1, HSP90AB2P | HDAC6 101/4885HDAC3 605/4885HDAC1 914/4885 |
| US-20250064838-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | HDAC6 735/4885HDAC3 2083/4885HDAC1 2966/4885 |
| US-12171772-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | HDAC6 735/4885HDAC3 2083/4885HDAC1 2966/4885 |
| US-11684629-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | HDAC6 735/4885HDAC3 2083/4885HDAC1 2966/4885 |
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | HDAC6 735/4885HDAC3 2083/4885HDAC1 2966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.